Although cocaine addiction remains a serious health and societal problem in the United States, no FDA-approved treatment has been developed. Vaccines offer an exciting strategy for the treatment of cocaine addiction; however, vaccine formulations need to be optimized to improve efficacy. Herein, we examine the effectiveness of a tricomponent cocaine vaccine, defined as having its hapten (GNE) and adjuvant (cytosine-guanine oligodeoxynucleotide 1826, CpG ODN 1826) covalently linked via the immunogenic protein ovalbumin (OVA). The tricomponent vaccine (GNE-OVA-CpG 1826) and a vaccine of analogous, individual components (GNE-OVA+CpG ODN 1826) were found to similarly induce highly specific anticocaine antibody production in mice and block cocaine’s stimulant effects in hyperlocomotor testing.

尽管可卡因成瘾在美国仍然是严重的健康和社会问题，但尚未开发出FDA批准的治疗方法。疫苗为治疗可卡因成瘾提供了令人兴奋的策略。但是，疫苗配方需要优化以提高功效。在本文中，我们检查了三组分可卡因疫苗的有效性，该疫苗被定义为通过免疫原性蛋白卵清蛋白（OVA）共价连接的半抗原（GNE）和佐剂（胞嘧啶-鸟嘌呤寡聚脱氧核苷酸1826，CpG ODN 1826）。发现三组分疫苗（GNE-OVA-CpG 1826）和类似的单个组分的疫苗（GNE-OVA + CpG ODN 1826）类似地诱导小鼠体内产生高特异性抗可卡因抗体，并在运动过度测试中阻断可卡因的刺激作用。